Allergan Extends Offer for Inamed
- Share via
From Reuters
Botox maker Allergan Inc. said it was extending its $3.2-billion offer to buy breast implant maker Inamed Corp. because it had yet to get antitrust clearance from regulators.
The offer is now set to expire at 8 p.m. on Feb. 7; it had been set to expire today.
Irvine-based Allergan and Santa Barbara-based Inamed said they were working with the Federal Trade Commission to complete the sale of Inamed’s license for Reloxin, a botulism toxin product.
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.
